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A bs tr ac t
Background
New-generation coronary stents that release zotarolimus or everolimus have been 
shown to reduce the risk of restenosis. However, it is unclear whether there are dif-
ferences in efficacy and safety between the two types of stents on the basis of pro-
spectively adjudicated end points endorsed by the Food and Drug Administration.
Methods
In this multicenter, noninferiority trial with minimal exclusion criteria, we ran-
domly assigned 2292 patients to undergo treatment with coronary stents releasing 
either zotarolimus or everolimus. Twenty percent of patients were randomly select-
ed for repeat angiography at 13 months. The primary end point was target-lesion 
failure, defined as a composite of death from cardiac causes, any myocardial infarc-
tion (not clearly attributable to a nontarget vessel), or clinically indicated target-
lesion revascularization within 12 months. The secondary angiographic end point 
was the extent of in-stent stenosis at 13 months.
Results
At least one off-label criterion for stent placement was present in 66% of patients. The 
zotarolimus-eluting stent was noninferior to the everolimus-eluting stent with respect 
to the primary end point, which occurred in 8.2% and 8.3% of patients, respectively 
(P<0.001 for noninferiority). There were no significant between-group differences in the 
rate of death from cardiac causes, any myocardial infarction, or revascularization. The 
rate of stent thrombosis was 2.3% in the zotarolimus-stent group and 1.5% in the 
everolimus-stent group (P = 0.17). The zotarolimus-eluting stent was also noninferior 
regarding the degree (±SD) of in-stent stenosis (21.65±14.42% for zotarolimus vs. 
19.76±14.64% for everolimus, P = 0.04 for noninferiority). In-stent late lumen loss was 
0.27±0.43 mm in the zotarolimus-stent group versus 0.19±0.40 mm in the everolimus-
stent group (P = 0.08). There were no significant between-group differences in the rate 
of adverse events.
Conclusions
At 13 months, the new-generation zotarolimus-eluting stent was found to be non-
inferior to the everolimus-eluting stent in a population of patients who had mini-
mal exclusion criteria. (ClinicalTrials.gov number, NCT00617084.)
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The use of early drug-eluting stents consisting of a metal platform and the con-trolled release of a therapeutic agent from 
a durable polymer matrix has partially addressed 
the problem of restenosis.1,2 Although these first-
generation polymers were considered biocompat-
ible, they have been associated with allergic reac-
tions and inflammation, which in combination 
with incomplete strut endothelialization have led 
to early and late stent thrombosis.3
New-generation polymer coatings aim more 
specifically at mimicking the endothelial lining 
in order to prevent thrombotic complications. In 
addition, basic research has shown that some of 
these polymeric materials could potentially up-
regulate genes related to thrombosis, inflamma-
tion, and vasoconstriction.4 The polymer used 
with the Resolute zotarolimus-eluting stent 
(Medtronic CardioVascular) is a mixture of a 
hydrophilic biocompatible component that faces 
the endoluminal surface and a hydrophobic com-
ponent that is attached to the metal stent surface 
and serves as a drug reservoir, enabling sus-
tained release of zotarolimus to control neointi-
mal hyperplasia in patients with complex condi-
tions and subgroups of lesions, as shown by 
encouraging early results.5-9
The purpose of this study, called the Resolute 
All Comers trial, was to compare the Resolute 
zotarolimus-eluting stent with an everolimus-
eluting stent (Xience V, Abbott Vascular Devices) 
in an unrestricted, multicenter, open-label, ran-
domized, controlled, noninferiority trial in pa-
tients undergoing percutaneous coronary inter-
vention (PCI) in everyday clinical practice.
Me thods
Patients
From April 30, 2008, to October 28, 2008, we 
recruited 2292 adult patients with chronic, stable 
coronary artery disease or acute coronary syn-
dromes, including myocardial infarction with or 
without ST-segment elevation. Patients were eli-
gible if they had at least one coronary lesion with 
stenosis of more than 50% in a vessel with a ref-
erence diameter of 2.25 to 4.0 mm. No restriction 
was placed on the total number of treated lesions, 
treated vessels, lesion length, or number of stents 
implanted. The exclusion criteria were a known 
intolerance to a study drug, metal alloys, or con-
trast media; planned surgery within 6 months 
after the index procedure; childbearing potential; 
and participation in another trial before reaching 
the primary end point.
At least one off-label criterion was present in 
1520 patients (66.3%). Off-label use included the 
placement of a stent in patients with at least one 
of the following clinical or lesion characteristics: 
renal insufficiency (creatinine level, ≥140 µmol 
per liter [1.6 mg per deciliter]), an ejection frac-
tion of less than 30%, the occurrence of acute 
myocardial infarction within the previous 72 
hours, more than one lesion per vessel, at least 
two vessels with stents, a lesion measuring more 
than 27 mm, bifurcations, bypass grafts, in-stent 
restenosis, unprotected left main artery (without 
a functioning bypass graft), lesions with throm-
bus, or total occlusion.
The study complied with the provisions of the 
Declaration of Helsinki, and the study protocol 
was approved by the institutional review board 
at each study center. All patients provided writ-
ten informed consent.
Study Design
Patients were randomly assigned to undergo PCI 
with a coronary stent releasing either zotaroli-
mus or everolimus. A subgroup of patients (20%) 
was randomly assigned to undergo angiographic 
follow-up at 13 months. The study-group assign-
ments were unknown to members of the inde-
pendent clinical events committee, steering com-
mittee, data-management committee, Academic 
Research Organization (Cardialysis), and the 
sponsor (Medtronic CardioVascular). The princi-
pal investigator and the coprincipal investigators 
designed the study, in collaboration with the 
sponsor. The verification of data collection was 
performed by an independent monitoring orga-
nization (Premier Research Group). The indepen-
dent group of statisticians at Academic Research 
Organization performed the analyses. Members 
of the steering committee wrote the first draft of 
the manuscript and vouch for the completeness 
and accuracy of the data gathering and analysis. 
The study was conducted in accordance with the 
trial protocol.
Study Procedures
The zotarolimus-eluting stent was available in 
diameters of 2.25, 2.50, 2.75, 3.00, 3.50, and 
4.00 mm and in lengths of 8 mm and 14 mm for 
stents with a diameter of 2.75 mm or less, 9 mm 
and 15 mm for stents with a diameter of 3.00 mm 
or more, and 12, 14, 18, 24, and 30 mm for all 
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available stent diameters. The everolimus-eluting 
stent was available in diameters of 2.25, 2.50, 
2.75, 3.00, 3.50, and 4.00 mm, with each avail-
able in lengths of 8, 12, 15, 18, 23, and 28 mm.
Balloon angioplasty and stent implantation 
were performed according to standard tech-
niques; direct stenting (without previous balloon 
dilatation) was allowed. The aim was to obtain 
full lesion coverage with one or multiple stents. 
No mixture of type of stents was permitted for 
a given patient unless the operator was unable to 
insert the study stent, in which case crossover to 
another nonstudy device of the operator’s choice 
was possible. The aim was to treat all coronary 
lesions in one session; however, staged procedures 
(defined as procedures planned at the time of the 
index procedure and performed within 6 weeks 
with the same type of study stent) were permit-
ted. In the case of unplanned revascularization 
procedures requiring stent implantation, it was 
recommended that physicians use the same type 
of study stent.
Procedural anticoagulation was achieved with 
unfractionated heparin at a dose of 5000 IU or 
70 to 100 IU per kilogram of body weight to 
maintain an activated clotting time of more than 
250 seconds; the use of glycoprotein IIb/IIIa in-
hibitors was left to the operator’s discretion. All 
patients who were enrolled in the study received 
at least 75 mg of acetylsalicylic acid before the 
procedure. A loading dose of 300 to 600 mg of 
clopidogrel was administered only if the patient 
had received no clopidogrel during the previous 
7 days. All patients were discharged with a pre-
scription for at least 75 mg of acetylsalicylic acid 
indefinitely and for 75 mg of clopidogrel for a 
minimum of 6 months after the index procedure.
At baseline, we evaluated all patients with a 
scoring system developed for the Synergy be-
tween PCI with Taxus and Cardiac Surgery 
(SYNTAX) study (ClinicalTrials.gov number, 
NCT00114972) to characterize the coronary vas-
culature regarding the number of lesions and 
their function, location, and complexity.10 The 
SYNTAX scale can range from 0 to 115, with a 
higher score indicating more complex disease.
Follow-up
Patients were followed up by telephone or hospi-
tal visit at 1, 6, and 12 months and will continued 
to be followed annually for 5 years. At outpatient 
visits, patients were specifically questioned about 
the occurrence of angina or any adverse event. 
Angiographic follow-up in 455 patients was 
planned at 13 months.
Quantitative Coronary Angiography
Findings on quantitative coronary angiography 
(QCA), which was performed with the use of the 
Cardiovascular Angiography Analysis System 
(CAAS) II (Pie Medical Imaging), were centrally 
assessed at one angiographic core laboratory 
(Cardialysis).11 QCA scans from patients return-
ing for any repeat angiography within 14 days 
after the index procedure were not used in the 
follow-up QCA analysis, since the need for repeat 
revascularization in this period was not related 
to neointimal hyperplasia but rather to an acute 
response of the lesion to the procedure. These 
methods are consistent with those used in previous 
coronary stent trials, such as the Sirolimus Elut-
ing Stent in de Novo Coronary Lesions (SIRIUS) 
trial (NCT00232765), and the Endeavor stent clini-
cal trial program (Mauri L, Harvard Clinical Re-
search Institute: personal communication). In 
addition, data from QCA analysis for patients re-
turning for any repeat angiography later than 
450 days (15 months) were also excluded from 
the statistical analysis, since they were outside 
the time limit for angiographic follow-up stipu-
lated in the protocol. Additional methods and 
definitions with respect to QCA are provided in 
the Methods section in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org.
Primary and Secondary End Points
The primary end point was target-lesion failure, 
defined as a composite of death from cardiac 
causes, any myocardial infarction (not clearly at-
tributable to a nontarget vessel), or clinically indi-
cated target-lesion revascularization at 12 months. 
Secondary clinical end points were a composite of 
death from any cause, any myocardial infarction 
(Q-wave or non–Q-wave), or any revascularization 
(either a percutaneous or surgical procedure with 
either a clinical or nonclinical indication), as well 
as the individual components of the composite; 
definite, probable, possible, and overall stent 
thrombosis, defined according to the Academic 
Research Consortium definition12; and acute pro-
cedure, device, and lesion success. (Definitions of 
all study end points are provided in the Methods 
section in the Supplementary Appendix.) Quanti-
tative angiographic end points included in-stent 
and in-segment percent stenosis, rate of binary 
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restenosis, minimal lumen diameter, and late lu-
men loss.
Statistical Analyses
This trial was powered for noninferiority testing 
of the primary end point at 12 months on an in-
tention-to-treat basis. Full details of the sample-
size calculation for the noninferiority primary and 
secondary end points are provided in the Methods 
section in the Supplementary Appendix.
Descriptive statistics for the secondary clini-
cal end points are provided. Categorical variables 
are reported as counts and percentages, and 
between-group differences were assessed with 
the use of Fisher’s exact test. Continuous vari-
ables are presented as means ±SD and were 
compared with the use of a two-sample t-test. 
The Kaplan–Meier method was used to calculate 
the time to clinical end points, and the log-rank 
test was used to compare between-group differ-
ences. Unless otherwise specified, a two-sided 
P value of less than 0.05 was considered to indi-
cate statistical significance.
R esult s
Patients
A total of 2292 patients with 3366 lesions were 
randomly assigned to receive either zotarolimus-
eluting stents (1140 patients with 1661 lesions) or 
everolimus-eluting stents (1152 patients with 1705 
lesions) (Fig. 1 in the Supplementary Appendix). A 
total of 21 patients (1.8%) in the zotarolimus-stent 
group and 26 (2.3%) in the everolimus-stent group 
were lost to follow-up or withdrew consent before 
the 12-month cutoff date, leaving 1119 patients in 
the zotarolimus-stent group and 1126 in the 
everolimus-stent group for inclusion in the inten-
tion-to-treat analysis.
Baseline clinical and angiographic character-
istics were similar in the two study groups (Ta-
bles 1 and 2). Total stent lengths per patient and 
per lesion were significantly higher in the 
everolimus-stent group (Table 2). However, this 
factor had no detrimental effect on 12-month 
clinical outcomes (Table 3, and Table 1 in the 
Supplementary Appendix).
The primary end point of target-lesion failure 
— a composite of death from cardiac causes, 
any myocardial infarction, or target-lesion revas-
cularization — occurred in 92 patients (8.2%) in 
the zotarolimus-stent group and 94 patients 
(8.3%) in the everolimus-stent group (Table 3 
and Fig. 1A). We confirmed noninferiority of the 
zotarolimus-eluting stent, with an absolute risk 
difference of −0.1% and the upper limit of the 
one-sided 95% confidence interval of 1.8% 
(P<0.001 in one-sided noninferiority analysis). 
The rates for the individual components of the 
primary end point were similar to those for the 
composite end point (Fig. 1B, 1C, and 1D). The 
findings for the primary end point were consis-
tent across prespecified stratified analyses (Fig. 
2 in the Supplementary Appendix).
Patients in the zotarolimus-stent group, as 
compared with the everolimus-stent group, had 
significantly reduced rates of death from any 
cause while they were hospitalized (0.1% vs. 
0.8%, P = 0.02) and at 30 days (0.2% vs. 0.9%, 
P = 0.04) because of a nonsignificant increased 
rate of death at 30 days in the everolimus-eluting 
stent group from both cardiac causes (0.2% vs. 
0.7%, P = 0.11) and noncardiac causes (0% versus 
0.2%, P = 0.50). At 12 months, the between-group 
difference in the rate of death from any cause 
was no longer significant (1.6% vs. 2.8%, 
P = 0.08) (Table 3).
At 12 months, the rate of definite stent throm-
bosis was significantly higher in the zotarolimus-
stent group (1.2%) than in the everolimus-stent 
group (0.3%, P = 0.01), which was primarily re-
lated to a higher rate of definite stent thrombo-
sis at 30 days in the zotarolimus-stent group 
(0.8%) than in the everolimus-stent group (0.1%, 
P = 0.01). Rates of probable or possible stent 
thrombosis and of the composite of definite, 
probable, or possible stent thrombosis were 
similar in the two groups at all time points 
(Table 3, and Table 1 in the Supplementary Ap-
pendix). A temporal breakdown of all definite 
and probable episodes of stent thrombosis, along 
with the worst hierarchical outcome during a 
12-month period, is shown in Figure 2 (for de-
tails, see the Results section and Table 2 in the 
Supplementary Appendix).
The secondary angiographic end point, the 
in-stent percent stenosis at 13 months, was de-
termined at a median of 401 days (interquartile 
range, 394 to 420) in the zotarolimus-stent group 
and 409 days (interquartile range, 395 to 426) in 
the everolimus-stent group. The percent stenosis 
achieved the prespecified criterion for noninferi-
ority, with 21.65±14.42% in the zotarolimus-
stent group versus 19.76±14.64% in the everoli-
mus-stent group, a difference of 2.03% measured 
as a least-square mean with an upper limit of 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA DEGLI STUDI DI MILANO on October 7, 2011. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 363;2 nejm.org july 8, 2010140
Table 1. Characteristics of the Patients at Baseline.*
Variable
Zotarolimus-Eluting 
Stent (N = 1140)
Everolimus-Eluting 
Stent (N = 1152)
Difference
(95% CI)†
Age — yr 64.4±10.9 64.2±10.8 0.2 (−0.7 to 1.1)
Male sex — no. (%) 874 (76.7) 889 (77.2) −0.5 (−4.0 to 2.9)
Coexisting condition — no. (%)
Diabetes mellitus 268 (23.5) 270 (23.4) 0.1 (−3.4 to 3.5)
Arterial hypertension 810 (71.1) 821 (71.3) −0.2 (−3.9 to 3.5)
Hyperlipidemia 729 (63.9) 780 (67.7) −3.8 (−7.6 to 0.1)
Cardiac risk factor
Current smoker — no. (%) 302 (26.5) 305 (26.5) 0.0 (−3.6 to 3.6)
Premature coronary artery disease in first-degree 
relative — no./total no. (%)
327/960 (34.1) 361/983 (36.7) −2.7 (−6.9 to 1.6)
Previous myocardial infarction — no./total no. (%) 324/1122 (28.9) 341/1120 (30.4) −1.6 (−5.4 to 2.2)
Previous percutaneous coronary intervention — 
no. (%)
363 (31.8) 370 (32.1) −0.3 (−4.1 to 3.5)
Previous coronary-artery bypass grafting — no. (%) 114 (10.0) 110 (9.5) 0.5 (−2.0 to 2.9)
Previous revascularization for angina or myo-
cardial infarction — no. (%)
996 (87.4) 1022 (88.7) −1.3 (−4.0 to 1.3)
Clinical characteristic
Stable angina — no. (%) 382 (33.5) 416 (36.1) −2.6 (−6.5 to 1.3)
Unstable angina — no. (%) 221 (19.4) 218 (18.9) 0.5 (−2.8 to 3.7)
Myocardial infarction — no. (%) 393 (34.5) 388 (33.7) 0.8 (−3.1 to 4.7)
Left ventricular ejection fraction <30% — no./ 
total no. (%)
17/610 (2.8) 13/608 (2.1) 0.7 (−1.1 to 2.4)
Multivessel disease — no. (%) 666 (58.4) 682 (59.2) −0.8 (−4.8 to 3.2)
Target-vessel location — no. (%)
Left main artery 25 (2.2) 29 (2.5) −0.3 (−1.6 to 0.9)
Left anterior descending artery 600 (52.6) 560 (48.6) 4.0 (−0.1 to 8.1)
Left circumflex artery 376 (33.0) 379 (32.9) 0.1 (−3.8 to 3.9)
Right coronary artery 425 (37.3) 476 (41.3) −4.0 (−8.0 to 0.0)
Bypass graft — no. (%) 28 (2.5) 28 (2.4) 0.0 (−1.2 to 1.3)
Complexity of coronary artery disease
No. of treated lesions per patient 1.46±0.73 1.48±0.77 −0.02 (−0.08 to 0.04)
SYNTAX score‡ 14.8±9.3 14.6±9.2 0.2 (−0.6 to 1.0)
At least one small vessel (reference vessel  
diameter, ≤2.75 mm) — no./total no. (%)
652/962 (67.8) 656/973 (67.4) 0.4 (−3.8 to 4.5)
At least one lesion length >18 mm — no./ 
total no. (%)
175/962 (18.2) 206/973 (21.2) −3.0 (−6.5 to 0.6)
At least one bifurcation or trifurcation — no./ 
total no. (%)
190/1126 (16.9) 202/1139 (17.7) −0.9 (−4.0 to 2.3)
At least one total occlusion — no./total no. (%) 184/1127 (16.3) 197/1145 (17.2) −0.9 (−4.0 to 2.2)
At least one in-stent restenosis — no./total no. (%) 91/1126 (8.1) 91/1139 (8.0) 0.1 (−2.1 to 2.3)
Off-label stent use — no. (%)§ 764 (67.0) 756 (65.6) 1.4 (−2.5 to 5.3)
* Plus–minus values are means ±SD. CI denotes confidence interval.
† The value is the difference in the zotarolimus-stent group, as compared with the everolimus-stent group.
‡ The SYNTAX score can range from 0 to 115, with higher scores indicating a greater complexity of disease.
§ Off-label stent use included the placement of a stent in a patient with at least one of the following clinical or lesion 
characteristics: renal insufficiency (creatinine level, ≥140 µmol per liter [1.6 mg per deciliter]), an ejection fraction of 
less than 30%, the occurrence of acute myocardial infarction within the previous 72 hours, more than one lesion per 
vessel, at least two vessels with stents, a lesion measuring more than 27 mm, bifurcation, bypass grafts, in-stent rest-
enosis, unprotected left main artery, lesions with thrombus, or total occlusion.
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4.73 for the one-sided 95% confidence interval 
(P=0.04 for noninferiority). Of note, there was 
a significant difference in in-segment late loss 
in favor of the everolimus-eluting stent, with 
0.15±0.43 mm in the zotarolimus-stent group 
versus 0.06±0.40 mm in the everolimus-stent 
group (P = 0.04), whereas no significant between-
group differences were observed for in-stent late 
loss (0.27±0.43 mm vs. 0.19±0.40 mm, P = 0.08), 
in-segment binary restenosis (5.2% vs. 6.5%, 
Table 2. Characteristics of Revascularization Procedures.*
Zotarolimus-Eluting 
Stent (N = 1140)
Everolimus-Eluting 
Stent (N = 1152)
Difference
(95% CI)† P Value
Before index procedure
Lesion length — mm
Mean 11.89±7.50 12.15±7.86 0.26 (−0.83 to 0.32)
Range 0.1–73.3 1.3–67.8
Reference vessel diameter — mm 2.63±0.57 2.63±0.58 0.00 (−0.04 to 0.05)
Minimum lumen diameter — mm 0.95±0.54 0.93±0.52 0.02 (−0.02 to 0.06)
Percent stenosis — % 63.59±18.41 64.18±18.19 −0.58 (−1.84 to 0.67)
Thrombus — no./total no. (%) 80/1518 (5.3) 75/1551 (4.8) 0.4 (−1.1 to 2.0)
Moderate or heavy calcification — no./total no. (%) 351/1599 (22.0) 323/1634 (19.8) 2.2 (−0.6 to 5.0)
TIMI score of 0 or 1 — no./total no. (%) 249/1635 (15.2) 264/1672 (15.8) −0.6 (−3.0 to 1.9)
After index procedure
No. of stents
Per patient 1.90±1.21 2.02±1.34 −0.12 (−0.23 to −0.02) 0.02
Per lesion 1.15±0.42 1.18±0.45 −0.03 (−0.06 to −0.01) 0.02
Total stent length — mm
Per patient 34.42±24.49 36.98±26.49 −2.56 (−4.65 to −0.47) 0.02
Per lesion 20.87±9.76 21.68±10.16 −0.81 (−1.44 to 0.18) 0.01
Balloon dilatation — no./total no. (%) 780/1122 (69.5) 799/1138 (70.2) −0.7 (−4.5 to 3.1) 0.75
Received study stent only — no./total no. (%) 1117/1140 (98.0) 1116/1152 (96.9) 1.1 (−0.2 to 2.4) 0.11
Minimum lumen diameter — mm
No. of lesions 1638 1674
In-stent 2.36±0.52 2.38±0.53 −0.01 (−0.05 to 0.02) 0.46
In-segment 2.06±0.54 2.06±0.55 0.00 (−0.04 to 0.03) 0.89
Diameter stenosis — %
In-stent 14.59±10.59 14.19±10.57 0.40 (−0.32 to 1.12) 0.28
In-segment 23.30±11.71 22.99±11.65 0.30 (−0.49 to 1.10) 0.46
Acute gain — mm
No. of lesions 1531 1557
In-stent 1.42±0.58 1.46±0.60 −0.04 (−0.08 to 0.01) 0.10
In-segment 1.11±0.59 1.13±0.62 −0.03 (−0.07 to 0.02) 0.22
Successful outcome — no./total no. (%)‡
Lesion 1869/1889 (98.9) 1946/1963 (99.1) −0.2 (−0.8 to 0.4) 0.62
Device 1820/1876 (97.0) 1888/1954 (96.6) 0.4 (−0.7 to 1.5) 0.52
Procedure 1060/1121 (94.6) 1063/1128 (94.2) 0.3 (−1.6 to 2.2) 0.79
* Plus–minus values are means ±SD. CI denotes confidence interval, and TIMI Thrombolysis in Myocardial Infarction.
† The value is the difference in the zotarolimus-stent group, as compared with the everolimus-stent group.
‡ Definitions for lesion, device, and procedural success are provided in the Methods section in the Supplementary Appendix.
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Table 3. Clinical Outcomes at 12 Months in the Intention-to-Treat Population.*
Outcome
Zotarolimus-Eluting 
Stent (N = 1119)
Everolimus-Eluting 
Stent (N = 1126)
Difference  
(95% CI)† P Value
no. (%)
Target-lesion failure‡ 92 (8.2) 94 (8.3) −0.1 (−2.4 to 2.2) 0.94
Death
From any cause 18 (1.6) 31 (2.8) −1.1 (−2.4 to 0.1) 0.08
From cardiac cause 15 (1.3) 19 (1.7) −0.3 (−1.4 to 0.7) 0.61
Target-vessel myocardial infarction§
Any 47 (4.2) 46 (4.1) 0.1 (−1.5 to 1.8) 0.92
Q-wave 8 (0.7) 5 (0.4) 0.3 (−0.4 to 0.9) 0.42
Non–Q-wave 40 (3.6) 41 (3.6) −0.1 (−1.6 to 1.5) 1.00
Clinically indicated target-lesion revascularization
Any 44 (3.9) 38 (3.4) 0.6 (−1.0 to 2.1) 0.50
Coronary-artery bypass grafting 6 (0.5) 8 (0.7) −0.2 (−0.8 to 0.5) 0.79
Percutaneous coronary intervention 38 (3.4) 31 (2.8) 0.6 (−0.8 to 2.1) 0.39
Myocardial infarction¶ 151 (13.5) 153 (13.6) −0.1 (−2.9 to 2.7) 0.95
Clinically indicated target-vessel revascularization
Any 55 (4.9) 54 (4.8) 0.1 (−1.7 to 1.9) 0.92
Coronary-artery bypass grafting 7 (0.6) 9 (0.8) −0.2 (−0.9 to 0.5) 0.80
Percutaneous coronary intervention 48 (4.3) 48 (4.3) 0.0 (−1.6 to 1.7) 1.00
Death from cardiac causes or target-vessel myocardial  
infarction§
60 (5.4) 61 (5.4) −0.1 (−1.9 to 1.8) 1.00
Major adverse cardiac event‖ 97 (8.7) 109 (9.7) −1.0 (−3.4 to 1.4) 0.42
Target-vessel failure** 101 (9.0) 108 (9.6) −0.6 (−3.0 to 1.8) 0.66
Patient-oriented composite end point†† 163 (14.6) 164 (14.6) 0.0 (−2.9 to 2.9) 1.00
Definite stent thrombosis (0–360 days)
All patients 13 (1.2) 3 (0.3) 0.9 (0.2 to 1.6) 0.01
Acute (0–1 day) 4 (0.4) 1 (0.1) 0.3 (−0.1 to 0.7) 0.22
Subacute (2–30 days) 5 (0.4)‡‡§§ 0 0.4 (0.1 to 0.8) 0.03
Late (31–360 days) 5 (0.4)‡‡ 2 (0.2) 0.3 (−0.2 to 0.7) 0.29
Probable stent thrombosis (0–360 days)
All patients (0–360 days) 6 (0.5) 5 (0.4) 0.1 (−0.5 to 0.7) 0.77
Acute (0–1 day) 1 (0.1)§§ 1 (0.1) 0.0 (−0.2 to 0.2) 1.00
Subacute (2–30 days) 3 (0.3) 4 (0.4) −0.1 (−0.5 to 0.4) 1.00
Late (31–360 days) 2 (0.2) 0 0.2 (−0.1 to 0.4) 0.25
Stent thrombosis (0–360 days)
Possible 9 (0.8) 9 (0.8) 0.0 (−0.7 to 0.7) 1.00
Definite or probable 18 (1.6) 8 (0.7) 0.9 (0.0 to 1.8) 0.05
Definite, probable, or possible 26 (2.3) 17 (1.5) 0.8 (−0.3 to 1.9) 0.17
* This trial was powered for noninferiority testing of the primary end point at 12 months on an intention-to-treat basis.
† The value is the difference in the zotarolimus-stent group, as compared with the everolimus-stent group.
‡ Target-lesion failure was defined as death from cardiac causes, any myocardial infarction (not clearly attributable to a nontarget vessel), or 
clinically indicated target-lesion revascularization.
§ Myocardial infarction was determined on the basis of the extended historical definition.13
¶ Myocardial infarction was determined on the basis of the Academic Research Consortium definition.12
‖ Major adverse cardiac events included a composite of death, myocardial infarction (Q-wave and non–Q wave), emergent coronary-artery 
bypass surgery, or repeat clinically indicated target-lesion percutaneous or surgical revascularization.
** Target-vessel failure was defined as death from cardiac causes, any myocardial infarction (not clearly attributable to a nontarget vessel), or 
clinically indicated target-vessel revascularization.
†† The patient-oriented composite end point was death from any cause, any myocardial infarction (Q-wave and non–Q wave), or any revascu-
larization.
‡‡ One patient had a definite stent thrombosis on both day 4 and day 31.
§§ One patient had a probable stent thrombosis on day 0 and a definite stent thrombosis on day 5.
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P = 0.67), or in-stent binary restenosis (4.2% vs. 
3.8%, P = 1.00) (Table 3 and Fig. 3 in the Supple-
mentary Appendix). The primary and secondary 
end points that were calculated on a per-protocol 
basis are reported in the Results section in the 
Supplementary Appendix.
Discussion
This study met the primary clinical end point by 
showing the noninferiority of the zotarolimus-
eluting stent, as compared with the everolimus-
eluting stent, when used in a population with 
minimal exclusion criteria. Historically, inclu-
sion criteria for enrollment in randomized trials 
of coronary stents have included patients with 
“on-label” indications, including those with sin-
gle de novo lesions of 27 mm or less in length in 
vessels with a reference diameter of 2.5 to 3.5 mm. 
Among patients who were commonly excluded 
from such studies were those with coexisting ill-
nesses, acute myocardial infarction, and multi-
vessel disease.
In 2006, a Food and Drug Administration 
panel formally recognized the biohazard of late 
stent thrombosis, a phenomenon that was ob-
served with increased frequency in the popula-
tions who had not been tested in previous ran-
domized trials of coronary stents. The use and 
the risk of drug-eluting stents in patients in 
whom the placement of such stents was consid-
ered to be off-label for the device became a 
major concern.14,15 It was recommended that 
future trials should address a broad, unselected 
patient population, which would be more repre-
sentative of everyday clinical practice. The lack 
of stringent exclusion criteria in our study re-
sulted in the enrollment of a large proportion of 
patients with acute myocardial infarction, multi-
vessel intervention, small-vessel disease, long 
lesions, or bifurcations or trifurcations — pa-
tients who represented those undergoing PCI in 
contemporary practice. Of note, results were 
consistent across all predefined subgroups.
In our study, we closely monitored the re-
cruitment of patients, which showed that 44% of 
all patients undergoing PCI were enrolled in the 
trial. Therefore, we consider that our findings 
are highly generalizable to patients in everyday 
clinical practice.
Given the overall complexity of the patient 
population, the event rates were low and com-
pared favorably with rates in previous “all-com-
er” studies, despite a somewhat higher mean 
SYNTAX score.16 Although the patient-oriented 
composite end point that was recommended by 
the Academic Research Consortium,13 which 
included all cardiovascular events, had an event 
rate of 14.6% in the two stent groups, this rate 
was lower than the rate of 18.3% reported in the 
angiographic group in the Fractional Flow Re-
serve Versus Angiography for Multivessel Evalu-
ation (FAME) study (NCT00267774) in the con-
text of a similar SYNTAX score.17
Using historical definitions of myocardial 
infarction, we compared rates in our trial with 
those in other all-comer trials.18-20 Before the 
start of the trial, it was decided that investiga-
tors should collect data on both creatine kinase 
and troponin levels, but the sponsor and the 
steering committee, in agreement with the data 
and safety monitoring board, decided to use the 
historical World Health Organization definitions 
of myocardial infarction, which were modified 
for an all-comer population.13 This decision was 
made to ensure that the trial results could be 
compared with historical coronary-stent studies. 
The measurement of troponin indeed resulted in 
a tripling of the rate of diagnosis of myocardial 
infarction. In the upcoming years, the increased 
sensitivity of the detection of troponin release will 
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Figure 2. Cumulative Incidence of Definite or Probable Stent Thrombosis.
Shown is the incidence of definite stent thrombosis (red) or probable stent 
thrombosis (blue) among 18 patients in the zotarolimus-stent group and  
8 patients in the everolimus-stent group, along with the worst hierarchical 
clinical outcome, over 360 days of follow-up. ARC denotes Academic Re-
search Consortium, and MI myocardial infarction.
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have to be carefully weighed against the reduced 
specificity for device-related coronary events.
Overall in our study, rates of stent thrombosis 
were low and similar to those in previous stud-
ies involving all comers or patients with acute 
coronary syndromes.18-22 Although we observed 
no significant between-group difference in over-
all rates of stent thrombosis, there were differ-
ences in rates of subacute definite events. We 
observed no significant between-group difference 
in the use of antiplatelet therapy, but there was 
a preponderance of stenting in the left anterior 
descending coronary artery and coexisting ill-
nesses in patients with stent thrombosis. It is 
noteworthy that these episodes of stent throm-
bosis did not result in an excessive rate of myocar-
dial infarction or death in the zotarolimus-stent 
group. Although our findings are hypothesis-
generating and require additional investigation, 
definitive conclusions will be obtained only from 
longer-term follow-up in large patient popula-
tions in studies that have sufficient statistical 
power to detect differences in rates of stent 
thrombosis.
In designing this trial, we wanted to subran-
domize a population for angiographic follow-up, 
and in order to prevent revascularization that 
was not clinically indicated, we postponed an-
giographic follow-up for 4 weeks after the final 
clinical follow-up. This resulted in a decline in 
compliance for angiographic follow-up, since the 
majority of asymptomatic patients who were re-
assured at the last clinic visit did not want to 
undergo repeat hospitalization for invasive angiog-
raphy 4 weeks later. A similar observation was 
noted in the Harmonizing Outcomes with Revas-
cularization and Stents in Acute Myocardial In-
farction (HORIZONS-AMI) trial (NCT00433966).21 
Despite this reduced compliance, the power of 
the angiographic follow-up study was maintained 
at more than 80% and can be interpreted with 
confidence. In view of the results of the in-stent 
and in-segment late loss, we concluded that 
there was no substantial difference between 
zotarolimus and everolimus in inhibitory effect 
on the neointima. Previously, the late loss ob-
served with the zotarolimus stent was 0.12 mm, 
0.22 mm, and 0.27 mm at 4, 9, and 13 months, 
respectively.5,6 Similarly, the previous late loss 
with the everolimus stent was 0.10 mm, 0.16 mm, 
0.19 mm, and 0.34 mm at 6, 8, 13, and 24 
months, respectively.23-25 If there is a difference 
in inhibition of neointimal hyperplasia, it must 
be underscored that these values of late loss are 
far from clinically relevant, as confirmed by the 
low and similar rates of binary restenosis.
In conclusion, the new-generation zotaroli-
mus-eluting stent was found to be as safe and 
effective as the everolimus-eluting stent in a 
group of patients for whom the procedure was 
considered to be predominantly off-label.
Supported by Medtronic CardioVascular.
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